SCHEMBL10205194

SCHEMBL10205194

CNC(=O)CN1CCCC(c2ccc(Nc3ncc(Cl)c(NCc4cccc5c4C(C)(C)C(=O)N5)n3)cc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 4/20 0.42
▸ NTRK1 P04629 7/20 0.40
▸ JUN P05412 2/20 0.40
▸ MAPK8 P45983 2/20 0.40
▸ MAPK9 P45984 2/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ MAPK10 P53779 1/20 0.40
▸ PTK2 Q05397 2/20 0.39
▸ ALK Q9UM73 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ STAT6 P42226 2/20 0.39
▸ STK17A Q9UEE5 1/20 0.39
▸ TNK2 Q07912 1/20 0.39
▸ NTRK3 Q16288 2/20 0.38
▸ NTRK2 Q16620 2/20 0.38
▸ KDR P35968 2/20 0.38
▸ FLT4 P35916 1/20 0.38
▸ JAK2 O60674 2/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ TTK P33981 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16255597 0.93 PTK2 (0.39) JAK3NTRK1JUNMAPK8MAPK9
SCHEMBL10205925 0.93 IGF1R (0.39) NTRK1JUNMAPK8MAPK9CDK2
SCHEMBL10206621 0.92 JAK3 (0.43) JAK3NTRK1PTK2ALKEGFR
SCHEMBL10205899 0.90 EGFR (0.39) JAK3NTRK1JUNMAPK8MAPK9
SCHEMBL10205202 0.90 JAK3 (0.40) JAK3NTRK1PTK2EGFRSTAT6
SCHEMBL10205197 0.87 ALK (0.43) JAK3NTRK1CDK2ALKSTK17A
SCHEMBL10206632 0.86 PTK2 (0.41) JAK3NTRK1PTK2ALKSTK17A
SCHEMBL10205930 0.83 PTK2 (0.35) JAK3JUNMAPK8MAPK9CDK2
SCHEMBL10206633 0.83 EGFR (0.46) JAK3NTRK1EGFRSTAT6STK17A
SCHEMBL10206145 0.83 NTRK1 (0.49) NTRK1PTK2STK17ATNK2NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 JAK3 1636/4885NTRK1 2690/4885JUN 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback